Literature DB >> 10799472

Secretory leukocyte protease inhibitor inhibits infection of monocytes and lymphocytes with human immunodeficiency virus type 1 but does not interfere with transcytosis of cell-associated virus across tight epithelial barriers.

H Hocini1, P Becquart, H Bouhlal, H Adle-Biassette, M D Kazatchkine, L Bélec.   

Abstract

In the present study, we demonstrate that recombinant human secretory leukocyte protease inhibitor (rhSLPI) inhibits infection of lymphocyte- and monocyte-derived tumor cell lines and peripheral blood lymphocytes with laboratory-adapted isolates and with the primary isolate, NDK, of free human immunodeficiency virus type 1 (HIV-1). In contrast, rhSLPI did not exhibit inhibitory activity toward transcytosis of cell-associated HIV-1 through a tight monolayer of endometrial epithelial cells. These observations indicate that the inhibitory effect of SLPI is restricted to free HIV-1 in corporal fluids.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10799472      PMCID: PMC95905          DOI: 10.1128/CDLI.7.3.515-518.2000

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  23 in total

1.  Intracellular neutralization of HIV transcytosis across tight epithelial barriers by anti-HIV envelope protein dIgA or IgM.

Authors:  M Bomsel; M Heyman; H Hocini; S Lagaye; L Belec; C Dupont; C Desgranges
Journal:  Immunity       Date:  1998-08       Impact factor: 31.745

2.  Epithelial uptake and transport of cell-free human immunodeficiency virus type 1 and gp120-coated microparticles.

Authors:  A Kage; E Shoolian; K Rokos; M Ozel; R Nuck; W Reutter; E Köttgen; G Pauli
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

3.  Secretory leukocyte protease inhibitor blocks infectivity of primary monocytes and mononuclear cells with both monocytotropic and lymphocytotropic strains of human immunodeficiency virus type I.

Authors:  D C Shugars; D L Sauls; J B Weinberg
Journal:  Oral Dis       Date:  1997-05       Impact factor: 3.511

4.  The elastase-induced expression of secretory leukocyte protease inhibitor is decreased in remodelled airway epithelium.

Authors:  V Marchand; J M Tournier; M Polette; B Nawrocki; C Fuchey; D Pierrot; H Burlet; E Puchelle
Journal:  Eur J Pharmacol       Date:  1997-10-08       Impact factor: 4.432

5.  High-level ability of secretory IgA to block HIV type 1 transcytosis: contrasting secretory IgA and IgG responses to glycoprotein 160.

Authors:  H Hocini; L Bélec; S Iscaki; B Garin; J Pillot; P Becquart; M Bomsel
Journal:  AIDS Res Hum Retroviruses       Date:  1997-09-20       Impact factor: 2.205

Review 6.  Secretory leukocyte protease inhibitor (SLPI) in mucosal fluids inhibits HIV-I.

Authors:  S M Wahl; T B McNeely; E N Janoff; D Shugars; P Worley; C Tucker; J M Orenstein
Journal:  Oral Dis       Date:  1997-05       Impact factor: 3.511

7.  Anatomic dissociation between HIV-1 and its endogenous inhibitor in mucosal tissues.

Authors:  S M Wahl; P Worley; W Jin; T B McNeely; S Eisenberg; C Fasching; J M Orenstein; E N Janoff
Journal:  Am J Pathol       Date:  1997-04       Impact factor: 4.307

8.  Localization and quantitation of a low molecular weight proteinase inhibitor, antileukoprotease, in the human uterus.

Authors:  B Casslén; M Rosengren; K Ohlsson
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1981-07

9.  Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase.

Authors:  R C Thompson; K Ohlsson
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

10.  HIV coreceptor downregulation as antiviral principle: SDF-1alpha-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication.

Authors:  A Amara; S L Gall; O Schwartz; J Salamero; M Montes; P Loetscher; M Baggiolini; J L Virelizier; F Arenzana-Seisdedos
Journal:  J Exp Med       Date:  1997-07-07       Impact factor: 14.307

View more
  26 in total

1.  Cervicovaginal levels of lactoferrin, secretory leukocyte protease inhibitor, and RANTES and the effects of coexisting vaginoses in human immunodeficiency virus (HIV)-seronegative women with a high risk of heterosexual acquisition of HIV infection.

Authors:  Richard M Novak; Betty A Donoval; Parrie J Graham; Lucy A Boksa; Gregory Spear; Ronald C Hershow; Hua Yun Chen; Alan Landay
Journal:  Clin Vaccine Immunol       Date:  2007-08-01

Review 2.  Anti-inflammatory and antimicrobial roles of secretory leukocyte protease inhibitor.

Authors:  Stergios Doumas; Alexandros Kolokotronis; Panagiotis Stefanopoulos
Journal:  Infect Immun       Date:  2005-03       Impact factor: 3.441

3.  Robust vaccine-elicited cellular immune responses in breast milk following systemic simian immunodeficiency virus DNA prime and live virus vector boost vaccination of lactating rhesus monkeys.

Authors:  Andrew B Wilks; Elizabeth C Christian; Michael S Seaman; Piya Sircar; Angela Carville; Carmen E Gomez; Mariano Esteban; Giuseppe Pantaleo; Dan H Barouch; Norman L Letvin; Sallie R Permar
Journal:  J Immunol       Date:  2010-11-01       Impact factor: 5.422

4.  Sex hormone regulation of innate immunity in the female reproductive tract: the role of epithelial cells in balancing reproductive potential with protection against sexually transmitted pathogens.

Authors:  Charles R Wira; John V Fahey; Mimi Ghosh; Mickey V Patel; Danica K Hickey; Daniel O Ochiel
Journal:  Am J Reprod Immunol       Date:  2010-03-29       Impact factor: 3.886

5.  Anti-HIV-1 activity of elafin is more potent than its precursor's, trappin-2, in genital epithelial cells.

Authors:  Anna G Drannik; Kakon Nag; Xiao-Dan Yao; Bethany M Henrick; Sumiti Jain; T Blake Ball; Francis A Plummer; Charles Wachihi; Joshua Kimani; Kenneth L Rosenthal
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

6.  Estradiol selectively regulates innate immune function by polarized human uterine epithelial cells in culture.

Authors:  J V Fahey; J A Wright; L Shen; J M Smith; M Ghosh; R M Rossoll; C R Wira
Journal:  Mucosal Immunol       Date:  2008-05-14       Impact factor: 7.313

7.  Short communication: HIV type 1 subtype C variants transmitted through the bottleneck of breastfeeding are sensitive to new generation broadly neutralizing antibodies directed against quaternary and CD4-binding site epitopes.

Authors:  Elizabeth S Russell; Suany Ojeda; Genevieve G Fouda; Steven R Meshnick; David Montefiori; Sallie R Permar; Ronald Swanstrom
Journal:  AIDS Res Hum Retroviruses       Date:  2013-01-18       Impact factor: 2.205

Review 8.  The mouth: a gateway or a trap for HIV?

Authors:  Daniel Malamud; Sharon M Wahl
Journal:  AIDS       Date:  2010-01-02       Impact factor: 4.177

9.  Human immunodeficiency virus type 1 is trapped by acidic but not by neutralized human cervicovaginal mucus.

Authors:  Samuel K Lai; Kaoru Hida; Shetha Shukair; Ying-Ying Wang; Anna Figueiredo; Richard Cone; Thomas J Hope; Justin Hanes
Journal:  J Virol       Date:  2009-08-19       Impact factor: 5.103

Review 10.  The oral mucosa immune environment and oral transmission of HIV/SIV.

Authors:  Lianna F Wood; Ann Chahroudi; Hui-Ling Chen; Heather B Jaspan; Donald L Sodora
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.